SCHOTT Pharma KGaA Valuation

Is 1SXP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1SXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1SXP (€27) is trading below our estimate of fair value (€30.2)

Significantly Below Fair Value: 1SXP is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1SXP?

Key metric: As 1SXP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1SXP. This is calculated by dividing 1SXP's market cap by their current earnings.
What is 1SXP's PE Ratio?
PE Ratio	27.3x
Earnings	€150.41m
Market Cap	€4.10b

1SXP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.6x
Enterprise Value/EBITDA	17.6x
PEG Ratio	1.7x

Price to Earnings Ratio vs Peers

How does 1SXP's PE Ratio compare to its peers?

The above table shows the PE ratio for 1SXP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	63.7x
GXI Gerresheimer	22.7x	21.6%	€2.6b
SRT3 Sartorius	193.8x	36.4%	€13.6b
DMP Dermapharm Holding	22.6x	18.1%	€2.0b
BIO3 Biotest	15.8x	29.3%	€1.4b
1SXP SCHOTT Pharma KGaA	27.3x	15.9%	€4.1b

Price-To-Earnings vs Peers: 1SXP is good value based on its Price-To-Earnings Ratio (27.3x) compared to the peer average (63.7x).

Price to Earnings Ratio vs Industry

How does 1SXP's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 1SXP is good value based on its Price-To-Earnings Ratio (27.3x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is 1SXP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1SXP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	27.3x
Fair PE Ratio	17.9x

Price-To-Earnings vs Fair Ratio: 1SXP is expensive based on its Price-To-Earnings Ratio (27.3x) compared to the estimated Fair Price-To-Earnings Ratio (17.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1SXP forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€27.00	€34.76 +28.8%	7.4%	€39.00	€31.80	n/a	11
Nov ’25	€29.56	€34.76 +17.6%	7.4%	€39.00	€31.80	n/a	11
Oct ’25	€30.74	€34.76 +13.1%	7.4%	€39.00	€31.80	n/a	11
Sep ’25	€35.64	€34.49 -3.2%	11.3%	€44.00	€30.00	n/a	11
Aug ’25	€31.76	€34.21 +7.7%	11.4%	€44.00	€30.00	n/a	11
Jul ’25	€31.42	€34.03 +8.3%	11.2%	€44.00	€30.00	n/a	11
Jun ’25	€29.28	€34.84 +19.0%	13.6%	€44.00	€25.00	n/a	11
May ’25	€40.10	€38.67 -3.6%	12.5%	€45.00	€30.00	n/a	10
Apr ’25	€39.20	€38.31 -2.3%	13.6%	€45.00	€30.00	n/a	9
Mar ’25	€39.00	€37.98 -2.6%	13.5%	€45.00	€30.00	n/a	8
Feb ’25	€36.60	€33.54 -8.4%	8.2%	€38.00	€30.00	n/a	8
Jan ’25	€33.80	€32.30 -4.4%	9.2%	€37.00	€27.50	n/a	8
Dec ’24	€29.40	€31.91 +8.6%	7.0%	€34.00	€27.50	n/a	7

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R74.3b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R9.00

0.6%

5.3%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

0.4%

-33.2%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.45

1.1%

2.9%